Screener / SEC EDGAR /CIK 0000914475 /10-K filed Feb 11, 2026, compared with Feb 10, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
Nasdaq Health care · Biotechnology

Neurocrine Biosciences Inc NBIX

Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. 10-K, Item 1

Headquarters
San Diego, CA
CEO
Kyle Gano
Next results
around Feb 10, 2027
Compare with peers Embed

Where each dollar of revenue went, FY2025

Revenue of $2.9B through the costs to a net profit of $478.6M · income statement of the 10-K

22% operating margin
Revenue to Gross profit: $2.8BRevenue to Cost of revenue: $52.1MGross profit to Operating profit: $619.1MGross profit to Operating expenses: $2.2BOperating profit to Net profit: $392.3MOperating profit to Tax: $226.8MOther income to Net profit: $86.3MOperating expenses to R&D: $1.0BOperating expenses to SG&A: $1.2B Revenue: $2.9B REVENUE $2.9B +21% Y/Y Gross profit: $2.8B · 98% margin GROSS PROFIT $2.8B 98% margin Cost of revenue: $52.1M · 2% of revenue COST OF REVENUE $52.1M 2% of revenue Operating profit: $619.1M · 22% margin OPERATING PROFIT $619.1M 22% margin · +9% Y/Y Other income: $86.3M · 3% of revenue OTHER INCOME $86.3M 3% of revenue Operating expenses: $2.2B · 77% of revenue OPERATING EXPENSES $2.2B 77% of revenue Net profit: $478.6M · 17% margin NET PROFIT $478.6M 17% margin · +40% Y/Y Tax: $226.8M · 8% of revenue TAX $226.8M 8% of revenue R&D: $1.0B · 36% of revenue R&D $1.0B 36% of revenue SG&A: $1.2B · 41% of revenue SG&A $1.2B 41% of revenue
Gross profit $2.8B 98% margin
Operating profit $619.1M 22% margin · +9% Y/Y
Net profit $478.6M 17% margin · +40% Y/Y
The full income statement, year by year

NBIX among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: 21.4%, above 78% of 154 peers (their median 10.4%) REVENUE GROWTH 21.4% · above 78% Operating margin: 24.0%, above 86% of 138 peers (their median 9.8%) OPERATING MARGIN 24.0% · above 86% Net margin: 19.0%, above 82% of 153 peers (their median 6.7%) NET MARGIN 19.0% · above 82% FCF margin: 28.1%, above 94% of 144 peers (their median 9.9%) FCF MARGIN 28.1% · above 94% Return on capital: 10.8%, above 62% of 89 peers (their median 9.0%) RETURN ON CAPITAL 10.8% · above 62%
NBIX Peer median Below the median

What changed

31 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 11, 2026 against Feb 10, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

1fact worth reading about the other 10 checks found nothing to note

  • Receivables growing faster than revenue
    Receivables +43.4% ($479.1M to $686.8M) vs revenue +21.4% ($2.4B to $2.9B), +21.9 pts apart
  • Cash from operations $782.7M vs net income $478.6M (FY ending Dec 31, 2025)
9 more checks with nothing to note
  • Inventory +20.2% ($57.4M to $69.0M) vs revenue +21.4% ($2.4B to $2.9B), -1.2 pts apart
  • Same auditor in both 10-Ks: Ernst & Young LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • The same matters as last year: Reserves for Medicaid rebates related to product sales
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

31 paragraphs in Risk Factors that were not in the 10-K filed Feb 10, 2025. Quoted as filed.

All 31 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 10, 2025 10-K, ITEM 1A
    Legislators, policymakers, and payors may continue to propose and implement cost-containing measures to keep healthcare costs down. For example, in April 2025, the President issued an executive order that, among other things, directed specified agency heads to develop a Center for Medicare and Medicaid Innovation (CMMI) model that…
  2. Item 1A · new paragraph · not in the 10-K filed Feb 10, 2025 10-K, ITEM 1A
    If any of our product candidates encounters any of these potential problems, we may never successfully market that product candidate. Because we believe our continued growth and success depend in part on our ability to identify (by internal development, in-license or acquisition), develop and ultimately commercialize a steady number of…
  3. Item 1A · new paragraph · not in the 10-K filed Feb 10, 2025 10-K, ITEM 1A
    Further, changes in federal policy could affect the geopolitical landscape and could give rise to circumstances that negatively affect our business. The third parties that manufacture our products have manufacturing facilities located in Europe. The U.S. has implemented, and has proposed to further implement, tariffs that may increase…
  4. Item 1A · new paragraph · not in the 10-K filed Feb 10, 2025 10-K, ITEM 1A
    New tax laws or regulations could be enacted at any time, and existing tax laws or regulations could be interpreted, modified, or applied in a manner that is adverse to us or our customers, which could adversely affect our business and financial condition. Federal laws such as the One Big Beautiful Bill Act (OBBBA), enacted in 2025, the…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$1.5B$1.9B$2.4B$2.9B
Net income$154.5M$249.7M$341.3M$478.6M
Operating cash flow$339.4M$389.9M$595.4M$782.7M
Free cash flow$322.9M$361.6M$557.2M$748.7M

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$2.9B ▲ 21.4% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

11 filings in the last 30 days · SEC EDGAR

All filings
6 more

About the company

Neurocrine Biosciences Inc, San Diego, CA · from the 10-K filed Feb 11, 2026

Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing, and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine, and immunological disorders. Our portfolio of products includes U.S. Food and Drug Administration (FDA) approved treatments for tardive dyskinesia (TD), chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (CAH), and endometriosis and uterine fibroids in collaboration with AbbVie Inc.

Headquarters
San Diego, CA
Country
United States
Reports in
USD
Listed on
Nasdaq
Fiscal year ends
December 31
Last results
Nov 2, 2026
Incorporated in
DE

Email alerts

Sources

The 10-K filed Feb 11, 2026 (open at SEC), compared with the 10-K filed Feb 10, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/NBIX/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.